<DOC>
	<DOCNO>NCT00514267</DOCNO>
	<brief_summary>To determine feasibility safety administer YM155 combination docetaxel</brief_summary>
	<brief_title>An Open-Label Study YM155 + Docetaxel Subjects With Advanced Hormone Refractory Prostate Cancer Other Solid Tumors</brief_title>
	<detailed_description>This clinical trial design include two part : Part 1 : Assessment feasibility safety administer YM155 combination docetaxel prednisone subject hormone refractory prostate cancer ( HRPC ) [ ENROLLMENT COMPLETED ] Part 2 : Assessment feasibility safety administer YM155 combination docetaxel subject solid tumor ( except HRPC ) . This registration update reflect design requirement PART 2 .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Part 1 : Male subject histologically cytologically confirm adenocarcinoma prostate clinical radiological evidence metastatic disease . Part 2 : Subjects histologically cytologically confirm solid tumor measurable disease ( except HRPC ) . Radiation therapy within 4 week start study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>HRPC</keyword>
	<keyword>Hormone Refractory Prostate Cancer</keyword>
	<keyword>YM155</keyword>
	<keyword>Treatment Outcome</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>